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haOBJECTIVES The study compared, by intravascular ultrasound (IVUS), acute gain (AG) at the site of the pre-procedural
minimal lumen area (MLA) achieved by either the Absorb (Abbott Vascular, Santa Clara, California) scaffold or the Xience
stent and identiﬁed the factors contributing to the acute performance of these devices.
BACKGROUND It is warranted that the acute performance of Absorb matches that of metallic stents; however, concern
exists about acute expansion and lumen gain with the use of Absorb.
METHODS Of a total of 501 patients (546 lesions) in the ABSORB II (ABSORB II Randomized Controlled Trial) ran-
domized trial, 445 patients with 480 lesions were investigated by IVUS pre- and post-procedure. Comparison of MLA
pre- and post-procedure was performed at the MLA site by matching pre- and post-procedural IVUS pullbacks.
RESULTS Lower AG on IVUS (lowest tertile) occurred more frequently in the Absorb arm than in the Xience arm
(3.46 mm2 vs. 4.27 mm2, respectively; p < 0.001; risk ratio: 3.04; 95% conﬁdence interval: 1.94 to 4.76). The plaque
morphology at the MLA cross-section was not independently associated with IVUS acute gain. The main difference in AG
in MLD by angiography was observed at the time of device implantation (Xience vs. Absorb, Dþ1.50 mm vs. Dþ1.23 mm,
respectively), whereas the gain from post-dilation was similar between the 2 arms (Dþ0.16 mm vs. Dþ0.16 mm) when
patients underwent post-dilation, although expected balloon diameter was smaller in the Absorb arm than in the Xience
arm (p ¼ 0.003) during post-dilation.
CONCLUSIONS At the site of the pre-procedural MLA, the increase of the lumen post-procedure was smaller in the
Absorb-arm than in the Xience arm. To achieve equivalent AG to Xience, the implantation of Absorb may require
more aggressive strategies at implantation, pre- and post-dilation than the technique used in the ABSORB II trial.
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1217AB BR E V I A T I O N S
AND ACRONYM S
IVUS = intravascular
ultrasound
MLA = minimal lumen area
MLD = minimal lumen diameter
QCA = quantitative coronary
angiographyT he fully bioresorbable scaffold is a noveldevice to treat coronary artery stenosis,potentially minimizing the long-term compli-
cations seen with metallic drug-eluting stents. The
everolimus-eluting Absorb bioresorbable vascular
scaffold (Absorb, Abbott Vascular, Santa Clara,
California) made of poly-L-lactide (PLLA) provides a
temporary coronary scaffolding for at least 6 months
and becomes fully resorbed by approximately 3 years
(1). The ﬁrst-in-humans trial using the Absorb showed
excellent safety results with potential late beneﬁts
such as late lumen enlargement and restoration of vas-
omotion (2). The ABSORB II (ABSORB II Randomized
Controlled Trial; NCT01425281) study is the ﬁrst ran-
domized trial between the Absorb scaffold and Xience
metallic stents in patients with up to 2 de novo native
coronary lesions (3,4).SEE PAGE 1228It is warranted that the acute performance of
Absorb matches that of metallic stents; however,
concern exists about acute expansion and lumen gain
with the use of a polymeric device. In the ABSORB
ﬁrst-in-humans trial, post-procedural intravascular
ultrasound (IVUS) imaging demonstrated that im-
plantation of an Absorb scaffold resulted in a more
eccentric lumen with nonhomogeneous scaffold
expansion compared with metallic stents (5).
Furthermore, nonrandomized matched population
from the ABSORB and SPIRIT trials demonstrated
that angiographic acute gain in lumen diameter tends
to be smaller in the Absorb than in the Xience (6).
This trend was also observed in the randomized
Japanese ABSORB trial (7–9). In the ABSORB II
randomized trial, pre-procedural and post-procedural
documentary IVUS imaging were mandatory and
provided a unique opportunity to evaluate the
scaffold/stent expansion at the precise site of pre-
procedural minimal lumen area (MLA) and to relate
the degree of expansion to the mechanical perfor-
mance of both devices, procedural parameters of
implantation and tissue composition derived from
IVUS analyses (4).
Therefore, the purpose of this study was to inves-
tigate the IVUS acute gain at the site of minimalreceived institutional research grants from Abbott Vascular, Biotronik, Boston
Jude Medical. Dr. van Geuns has received speaker fees and institutional res
received speaker fees and travel support from Abbott Vascular. Dr. Gershlick
AstraZeneca. Drs. Grundeken and de Winter have received institutional gra
ported that they have no relationships relevant to the contents of this pape
equally to this work.
Manuscript received December 31, 2015; revised manuscript received Februlumen area between the Absorb scaffold and
the Xience stent and to identify the factors
contributing to the acute performance of
these devices.
METHODS
STUDY DESIGN AND POPULATION. The
ABSORB II study was a randomized
controlled trial comparing the safety and efﬁcacy of
the Absorb everolimus-eluting bioresorbable vascular
scaffold and the Xience everolimus-eluting metallic
stent in patients with up to 2 de novo native coronary
lesions. Details of the study are available elsewhere
(3). After successful pre-dilation of the target lesion,
2:1 randomization was performed. Of a total of 501
patients (546 lesions), 335 patients (364 lesions) were
randomly assigned to receive Absorb device, and 166
patients (182 lesions) were assigned to receive the
Xience device. Grayscale IVUS and IVUS-virtual his-
tology (VH) imaging pre-procedure and post-
implantation was mandatory but documentary. No
treatment recommendation on the basis of IVUS im-
aging was made in the protocol.
STUDY DEVICE. The Absorb device has an amorphous
poly-DL-lactide (PDLLA) coating that contains and
controls the release of the antiproliferative drug ever-
olimus. The scaffold is made of semicrystalline PLLA.
PLLA is completely biodegraded by hydrolysis into
water and CO2 via the Krebs cycle. Physically, the
scaffold has struts with an approximate thickness of
150 mm. The Xience device is an everolimus-eluting,
cobalt chromium alloy device with a platform consist-
ing of serpentine rings connected by links fabricated
from a single piece. The overall strut thickness
including the drug coating is approximately 90 mm.
PROCEDURE AND IVUS ACQUISITION. Pre-procedural
IVUS was mandatory before dilation of the target
lesion. If it was not technically feasible (e.g., the IVUS
catheter could not cross the lesion), pre-dilation with
a small balloon was allowed to facilitate the IVUS
catheter insertion.
IVUS images were obtained with a rotational
45-MHz IVUS catheter (Revolution, Volcano Corp.,Scientiﬁc, Medtronic, Edwards Lifesciences, and St.
earch grants from Abbott Vascular. Dr. Bartorelli has
has received lecture fees from Abbott Vascular and
nts from Abbott Vascular. All other authors have re-
r to disclose. Drs. Sotomi and Ishibashi contributed
ary 29, 2016, accepted March 21, 2016.
FIGURE 1 Study Flow Chart
Of 501 patients with 546 lesions, enrolled in the ABSORB II trial, 445 patients with 480 lesions (291 patients with 313 lesions in Absorb and 154
patients with 167 lesions in Xience) had both pre-procedural and post-procedural IVUS analyses for acute lumen area gain at the original
minimal lumen area site. pts ¼ patients.
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1218Rancho Cordova, California). After intracoronary in-
jection of 200 mg of nitroglycerin, IVUS pullbacks
were performed with the use of an automated
motorized device at a pullback speed of 0.5 mm/s.
Lesions were treated with routine interventional
techniques that included mandatory pre-dilation
with a balloon shorter and 0.5 mm smaller in diam-
eter than the study device. The size of stent/scaffold
was determined by the target vessel diameter, which
was measured by pre-procedural on-line quantitative
coronary angiography (QCA) (3,10). All patients
enrolled in the ABSORB II trial were treated as fol-
lows: 1) a 3.5-mm device was used when both the
proximal and distal maximal lumen diameters were
within an upper limit of 3.8 mm and a lower limit
of 3.0 mm; 2) a 3.0-mm device was used when both
the proximal and the distal maximal lumen diameters
were within an upper limit of 3.3 mm and a lower
limit of 2.5 mm; 3) a 2.5-mm device was used when
both the proximal and the distal maximal lumen di-
ameters were within an upper limit of 3.0 mm and a
lower limit of 2.25 mm; and 4) scaffold/stent overlap
was allowed. Post-dilation with a balloon shorter than
the implanted scaffold/stent was performed at thediscretion of the operators. Post-procedural IVUS
images were obtained at the end of the procedure
(post-device implantation or post-dilation). All pull-
backs were analyzed ofﬂine by an independent
core laboratory (Cardialysis BV, Rotterdam, the
Netherlands) using commercially available software
(QIvus version 2.2, Medis, Leiden, the Netherlands).
MEASUREMENT OF ACUTE GAIN ON IVUS. To assess
the acute performance of the Absorb and Xience stent
at the site of the worst stenosis pre-procedure, the
difference of lumen area between pre- and post-
procedural IVUS images at the site of the pre-
procedural minimal lumen area (MLA) was measured
as acute gain in MLA. Pre-procedural MLA was deﬁned
as the smallest lumen area within the target lesion.
After identifying the frame of the pre-procedural MLA
site, matching of pre- and post-procedural IVUS im-
ages was performed by identifying common land-
marks, such as side branches, bifurcations, large
calciﬁcations, or echogenic metallic marker on the
device. Matching was performed using a dedicated
software (QCU-CMS software, Medis). The pre-
procedural image of the MLA was matched and
TABLE 1 Clinical Characteristics and Procedural Variables (N ¼ 445)
Absorb
(N ¼ 291)
Xience
(N ¼ 154) p Value
Demographics
Males 217 (74.6) 123 (79.9) 0.241
Age (y) 61  10 61  10 0.786
Current smoking 77 (26.5) 33 (21.4) 0.251
Lipid disorder requiring medication 201 (69.1) 116 (75.3) 0.258
Hypertension requiring medication 188 (64.6) 104 (67.5) 0.802
Diabetes mellitus 64 (22.0) 38 (24.7) 0.554
Stable angina 187 (64.3) 100 (64.9) 0.917
Body mass index (kg/m2) 27.8  4.1 28.1  3.7 0.542
Obesity (BMI $30 kg/m2) 67 (23.1) 44 (28.6) 0.208
Lesions (N ¼ 480) 313 lesions 167 lesions
Pre-procedural angiography
Lesion location 0.184
Left anterior descending artery 146 (46.7) 81 (48.5)
Left circumﬂex artery 88 (28.1) 35 (21.0)
Right coronary artery 79 (25.2) 51 (30.5)
Lesion classiﬁcation† 0.456
A 4 (1.3) 1 (0.6)
B1 181 (58.0) 85 (51.5)
B2 125 (40.1) 78 (47.3)
C 2 (0.6) 1 (0.6)
Quantitative coronary angiography
Interpolated percent diameter
stenosis (%)
58.3  11.1 59.1  11.4 0.448
Minimal lumen diameter (mm) 1.08  0.32 1.07  0.31 0.627
Reference vessel diameter (mm) 2.60  0.37 2.64  0.40 0.327
Maximal diameter at proximal reference
segment (mm)
2.84  0.45 2.87  0.46 0.476
Maximal diameter at distal reference
segment (mm)
2.69  0.45 2.74  0.43 0.258
Procedural variables
Pre-dilation
Pre-dilation before IVUS 115 (36.7) 59 (35.3) 0.842
Pre-dilation performed 313 (100.0) 165 (98.8) 0.121
Nominal diameter of pre-dilation
balloon (mm)
2.60  0.36 2.64  0.35 0.236
Maximal pressure during pre-dilation (atm) 12.2  3.0 12.5  3.1 0.300
Device implantation
Nominal diameter of device 0.139
2.5 mm 52 (16.6) 17 (10.2)
2.75 mm 0 (0) 1 (0.6)
3.0 mm 190 (60.7) 107 (64.1)
3.5 mm 71 (22.7) 42 (25.1)
Maximal pressure during device
implantation (atm)
13.1  2.7 13.8  2.5 0.008*
Expected inner device diameter (mm) 3.34  0.33 3.28  0.33 0.109
Post-dilation
Post-dilation performed 194 (62.0) 102 (61.1) 0.844
Nominal diameter of post-dilation
balloon (mm)‡
3.16  0.34 3.28  0.37 0.01*
Maximal pressure during post-dilation (atm)§ 15.3  3.2 16.7  3.4 0.001*
Expected diameter of post-dilation balloon (mm)§ 3.27  0.35 3.40  0.39 0.003*
Maximal expected diameter of balloon
(with or without post-dilation) (mm)
3.37  0.33 3.38  0.36 0.896
Values are n (%) or mean  SD. *p < 0.05. †Data were available in 477 lesions. ‡Data were available in 292
lesions. §Data were available in 290 lesions.
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1219compared with the post-procedural lumen area at the
same site. The lower acute gain was deﬁned as the
lowest tertile from the whole population.
ANALYSIS OF IVUS AND PROCEDURAL PARAMETERS.
Contour detection was performed by experienced
IVUS core laboratory analysts who were unblinded to
the device type. IVUS metrics including vessel, stent/
scaffold, and lumen area were measured at 0.5-mm
intervals. To identify the lesion factors in the evalua-
tion of acute gain, analysis was also performed using
the following parameters: plaque burden, lumen ec-
centricity, presence of calcium, remodeling index (11)
from grayscale IVUS and tissue composition parame-
ters (absolute value and percentage) from IVUS-VH.
Plaque burden was obtained by the plaque plus me-
dium cross-sectional area divided by the vessel cross-
sectional area (12). Eccentricity index was calculated
as the ratio of the projected minimal and maximal
lumen or scaffold/stent diameter at the MLA cross-
section (5,13). Pre-treatment reference segments
were selected as sites with the least amount of plaque
proximal and distal to the MLA sites before the take-
off of any major side branch (11). The remodeling in-
dex (RI) was calculated as the vessel area at the MLA
site divided by the average of the proximal and distal
reference vessel areas. Negative remodeling was
deﬁned as an RI <0.88, intermediate remodeling as an
RI of 0.88 to 1.00, and positive remodeling as an RI
>1.00 (11).
Location and circumferential distribution of cal-
cium was quantiﬁed in grayscale IVUS. Calcium was
deﬁned as bright echoes with acoustic shadowing.
The location of the calcium was deﬁned as superﬁcial,
deep, or both (14). If the leading edge of the acoustic
shadowing appeared within the shallowest 50% of the
plaque thickness, it was deﬁned as superﬁcial cal-
cium. If the leading edge of the acoustic shadowing
appeared within the deepest 50% of the plaque
thickness, it was deﬁned as deep calcium. The largest
continuous arc of calcium and summed arc of calcium
at the site of pre-interventional lumen area were
measured in degrees with a protractor centered on the
lumen. In addition, the arc of calcium was classiﬁed
as 1 quadrant (#90), 2 quadrants (91 to 180), 3
quadrants (181 to 270), or 4 quadrants (271 to 360).
By IVUS-VH analysis, tissue at the site of pre-
procedural MLA was divided into 4 basic plaque tis-
sue components: ﬁbrous tissue, ﬁbrofatty tissue,
necrotic core, and dense calcium (15).
In the compliance charts (pressure-diameter re-
lationships) for Absorb and Xience (Prime, Xpedition,
and so forth) provided by the manufacturer, the inner
FIGURE 2 Representative Case of IVUS Acute Gain
Examples of IVUS pullbacks before (A–E) and after procedure (F–I). Vessel and lumen contours were drawn (C) at the site of pre-procedural
minimal lumen area (dotted line in longitudinal view [E, F]). Calcium, deﬁned as bright echoes with acoustic shadowing, was measured in its
circumferential extension (largest continuous arc of calcium [solid arc]: 101.3, summed arc of calcium [solid and dotted arcs]: 214.1 [B]), and
location (superﬁcial calcium). Tissue component (D) was assessed by IVUS-VH. After matching pre- (E) and post-procedural IVUS pullbacks (F),
vessel and lumen areas were obtained at the corresponding site (H). Lumen area in C was 1.77 mm2 and 4.87 mm2 in H. Therefore, acute lumen
gain was 3.10 mm2 (green line ¼ vessel contour; red line ¼ lumen contour; blue asterisk ¼ side branch; blue dagger ¼ calciﬁcation).
LA ¼ lumen area; MLA ¼ minimal lumen area; IVUS-VH ¼ intravascular ultrasound-virtual histology.
Sotomi et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 2 , 2 0 1 6
IVUS Acute Gain in Absorb Versus Xience J U N E 2 7 , 2 0 1 6 : 1 2 1 6 – 2 7
1220diameters of the devices were described. Expected
device diameter was obtained from the device
compliance chart, using the nominal device diameter
and the maximal pressure during implantation. Dur-
ing post-dilation, the expected balloon diameter was
obtained from the balloon compliance chart data
provided by the various manufacturers of balloons,
using the nominal diameter of the balloon and the
maximal pressure during the procedure. In case the
pressure during the procedure exceeded the highest
pressure on the chart, the highest diameter on the
chart was used for the calculation.ANGIOGRAPHIC ASSESSMENT. Online QCA analyses
were undertaken by the sites before Absorb implan-
tation to deﬁne Dmax (10), and pre- and post-
procedural ofﬂine QCA were performed by an
independent core laboratory (Cardialysis BV) using the
coronary angiography analysis system (Pie Medical
Imaging, Maastricht, the Netherlands). The minimal
lumen diameter (MLD) changes at different phases of
the procedure were measured before procedure, after
device implantation, and immediately after post-
dilation. Additionally, minimal diameter of balloon
was measured during scaffold/stent implantation at
TABLE 2 IVUS Data at the Site of Pre-Procedural Minimal Lumen Area (N ¼ 480)
Data
Pre-Procedure Post-Procedure Change From Pre to Post
Absorb
(n ¼ 313)
Xience
(n ¼ 167) p Value
Absorb
(n ¼ 313)
Xience
(n ¼ 167) p Value
Absorb
(n ¼ 313)
Xience
(n ¼ 167) p Value
Grayscale IVUS
Lumen area (mm2) 2.08  0.76 2.13  0.85 0.502 5.55  1.46 6.40  1.68 <0.001 3.46  1.35 4.27  1.46 <0.001
Vessel area (mm2) 10.71  3.67 11.61  3.89 0.014 13.05  3.83 14.28  4.01 0.001 2.34  1.80 2.66  1.82 0.066
Plaque area (mm2) 8.63  3.47 9.47  3.71 0.016 7.51  2.82 7.88  2.94 0.181 1.12  1.75 1.60  1.76 0.005
Plaque burden (%) 79.0  8.3 80.2  8.5 0.143 56.4  8.1 54.3  7.8 0.007 22.6  8.2 25.9  7.3 <0.001
Minimal lumen diameter (mm) 1.47  0.23 1.48  0.25 0.660 2.41  0.37 2.66  0.45 <0.001
Maximal lumen diameter
(mm)
1.75  0.37 1.77  0.38 0.591 2.86  0.40 3.00  0.41 <0.001
Lumen eccentricity 0.86  0.10 0.85  0.10 0.711 0.84  0.08 0.89  0.11 <0.001
Presence or absence of
calcium (%)
0.987
No 114 (36.4) 61 (36.5)
1 quadrant (1w90) 130 (41.5) 67 (40.1)
2 quadrants (91w180) 41 (13.1) 24 (14.4)
3 quadrants (181w270) 15 (4.8) 9 (5.4)
4 quadrants (270w360) 13 (4.2) 6 (3.6)
Largest continuous arc of
calcium ()
45.5  58.8 51.8  67.0 0.306
Summed arc of calcium () 54.3  69.3 60.7  75.0 0.362
Remodeling pattern (%)* 0.802
Positive remodeling 94 (30) 46 (28)
Intermediate remodeling 83 (27) 43 (26)
Negative remodeling 132 (42) 75 (45)
IVUS-VH
Fibrous tissue (% of total
plaque area)
27.70  16.07 26.70  14.69 0.504 27.30  10.99 21.71  8.86 <0.001 0.41  15.11 4.99  15.22 0.002
Fibrofatty tissue (% of total
plaque area)
52.70  22.81 54.00  21.61 0.551 31.49  19.77 30.08  17.65 0.440 21.25  20.07 23.92  17.17 0.139
Necrotic core (% of total
plaque area)
15.64  10.23 15.48  9.94 0.867 28.58  10.70 30.65  10.12 0.043 13.03  10.96 15.17  10.65 0.044
Dense calcium (% of total
plaque area)†
3.95  6.02 3.82  5.81 0.822 12.56  11.21* 17.56  12.90* <0.001 8.56  10.13 13.74  12.47 <0.001
Values are mean  SD or n (%). *7 are missing data. †The polymeric or metallic struts are detected as (pseudo)calcium on IVUS-VH.
IVUS-VH ¼ intravascular ultrasound-virtual histology.
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1221maximal inﬂation pressure and during post-dilation at
maximal inﬂation pressure.
Acute recoil was deﬁned as follows: When a stent/
scaffold delivery balloon was used for stent/scaffold
expansion, acute absolute stent/scaffold recoil was
deﬁned as the difference between the mean diameter
of the stent/scaffold delivery balloon at the highest
pressure at implantation of the stent/scaffold (X) and
the mean luminal diameter of the stented/scaffolded
segment after implantation (Y). Acute absolute stent/
scaffold recoil was calculated as: [X – Y]. When a post-
dilation balloon was used in the procedure, acute ab-
solute recoil was deﬁned as the difference between the
mean diameter of the post-dilation balloon at the
highest pressure in the post-dilated segment (X0) and
themean luminal diameter after post-dilation (Y0). The
angiogram of X and Y was performed in the sameangiographic view so that the 2 images were perfectly
matched.
STATISTICAL ANALYSIS. Categorical variables are
presented as counts and percentages. Continuous
variables are presented as mean  SD. A p value
of <0.05 was considered statistically signiﬁcant.
Generalized estimating equations modeling was per-
formed to take into an account the clustered nature of
>1 stents/scaffolds per patient, which might result in
unknown correlations among measurements within
these scaffold clusters. Paired analysis was performed
in the patients with analyzable pre- and post-
procedural IVUS images. Logistic regression analysis
was performed to ﬁnd the relationship of the
following factors with IVUS lower acute gain in lumen
area: sex, age, obesity (body mass index $30 kg/m2),
FIGURE 3 Cumulative Frequency Distribution Curve of Pre- and Post-MLA and
Acute Gain
Cumulative frequency distribution curve of AG at the MLA site pre-procedure [AG ¼
(MLApost – MLApre)] for Absorb and Xience. Pre-procedural MLA was similar between the 2
arms. The post-procedural lumen area at the site of the pre-procedural MLA was signiﬁ-
cantly smaller in the Absorb arm than in the Xience arm (5.55 mm2 vs. 6.40 mm2,
respectively; p < 0.001). The amount of change in lumen area was signiﬁcantly smaller in
the Absorb arm than in the Xience arm (3.46 mm2 vs. 4.27 mm2, respectively; p < 0.001).
AG ¼ acute gain; MLA ¼ minimal lumen area.
FIGURE 4 Device Expansion of Absorb and Xience
When device expansion was deﬁned as the ratio of post-procedural lumen area at the site
of the pre-procedural MLA to the expected inner device area calculated from the largest
balloon used during procedure, the Absorb scaffold achieved, on average, 62  12% only
of the predicted lumen area, whereas the Xience stent achieved 71  15% (p < 0.001).
MLA ¼ minimal lumen area.
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1222treated vessel, pre-procedural MLA, pre-procedural
lumen eccentricity, plaque area, and vessel area (all
measurements at the site of MLA). In addition, pres-
ence or absence of calcium as well as arc of calcium at
the site of MLA, tissue composition at the site of MLA,
remodeling index (11), type of stent/scaffold, and
maximal expected inner device or balloon diameter
throughout procedure (in cases with or without post-
dilation) were also included in the logistic regression
analysis. In the multivariate model, MLA was not
included due to strong interaction with plaque area
and vessel area. Statistical analyses were performed
with SPSS version 23.0.0 software (IBM, Armonk, New
York).
RESULTS
BASELINE CHARACTERISTICS. Of 501 patients with
546 lesions who were enrolled in the ABSORB II trial,
445 patients with 480 lesions (291 patients with
313 lesions in the Absorb arm and 154 patients with
167 lesions in the Xience arm) had both pre-
procedural and post-procedural IVUS analyses for
acute lumen area gain assessment (Figure 1). There
were no signiﬁcant differences in baseline patient
demographics and pre-procedural angiography data
(Table 1).
DIFFERENCES IN PROCEDURAL IMPLANTATION
STRATEGY BETWEEN ABSORB AND XIENCE.
Table 1 indicates the differences in procedural strat-
egy between Absorb and Xience. Pre-dilation strategy
was comparable between both arms. At the time of
the device implantation, no differences in device size
selection and expected inner device diameter were
observed, whereas maximal pressure during device
implantation was higher in Xience than in Absorb. At
the time of post-dilation, nominal diameter of the
balloon, maximal pressure, and expected balloon
diameter were smaller in the Absorb arm than in the
Xience arm.
IVUS ANALYSIS. A representative case of acute gain
in MLA is presented in Figure 2. Overall, the pre-
procedural MLA was comparable between the 2
arms. However, pre-procedural vessel area (Xience
11.61 mm2 vs. Absorb 10.71 mm2, respectively; p ¼
0.014) and plaque area (Xience 9.47 mm2 vs. Absorb
8.63 mm2, respectively; p ¼ 0.016) at the site of MLA
were signiﬁcantly larger in the Xience arm than in the
Absorb arm. The post-procedural lumen area at the
site of pre-procedural MLA was signiﬁcantly smaller
in the Absorb arm (5.55 mm2 vs. 6.40 mm2, respec-
tively; p < 0.001). The amount of change in plaque
area and plaque burden was signiﬁcantly smaller in
FIGURE 5 Relationship Between Circumferential Distribution of Calcium and Acute Gain
The relationship between circumferential distribution of calcium and acute gain (blue circles ¼ Absorb; red circles ¼ Xience). Presence or absence of calcium as well as
the arc of calcium by IVUS grayscale did not affect acute gain and device expansion at the site of minimal lumen area. IVUS ¼ intravascular ultrasound; MLA ¼ minimal
lumen area.
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1223the Absorb arm than in the Xience arm (1.12 mm2
vs. 1.60 mm2, respectively; p ¼ 0.005; and 22.6%
vs. 25.9%, respectively; p < 0.001). The increase of
vessel area tended to be smaller in the Absorb arm
(2.34 mm2 vs. 2.66 mm2, respectively; p ¼ 0.066). As
a result, there were signiﬁcant differences in acute
gain for the minimal lumen areas (3.46 mm2 vs.
4.27 mm2, respectively; p < 0.001) (Table 2, Figure 3).
DEVICE EXPANSION IN MINIMAL LUMEN AREA.
When device expansion (16,17) was deﬁned as the
ratio of post-procedural lumen area at the site of pre-
procedural MLA to the expected inner device area
calculated from the largest balloon used during pro-
cedure, the Absorb scaffold achieved on average 62 
12% of the predicted lumen area, whereas the Xience
stent achieved 71  15% (p < 0.001) (Figure 4). Loca-
tion of calcium as well as the arc of calcium and the
amount of NC did not affect device expansion
(Figure 5).QCA MLD CHANGES AT DIFFERENT PHASES DURING
PROCEDURE. Figure 6 shows the MLD by QCA and
MLA by IVUS changes at different phases during the
procedure in the patients who had both pre- and post-
procedural IVUS analyses.
The Main difference in acute gain in MLD by QCA
was observed at the time of device implantation
(Xience vs. Absorb, Dþ1.50 mm vs. Dþ1.23 mm,
respectively), whereas the gain from post-dilation
was similar between the 2 arms (Dþ0.16 mm vs.
Dþ0.16 mm) when patients underwent post-dilation.
Acute recoil during device implantation was similar
in both devices (Xience vs. Absorb, 0.20  0.18 mm
vs. 0.19  0.19 mm, respectively; p ¼ 0.716), whereas
acute recoil during post-dilation was larger in the
Xience than in the Absorb (0.21  0.21 mm vs. 0.13 
0.20 mm, respectively; p ¼ 0.006).
PREDICTORS OF LOWER ACUTE GAIN. Lower acute
gain (lowest tertile) occurred more frequently in
FIGURE 6 Minimal Lumen Diameter Changes by QCA and MLA Changes by IVUS at Different Phases of the Procedure
The minimal lumen diameter changes by QCA (line graph) and MLA changes by IVUS (bar graph) at different phases of the procedure in
patients who had both pre- and post-procedural IVUS analyses. Change of MLD by QCA and MLA by IVUS of the Absorb and the Xience are
depicted by blue and red, respectively. Dotted lines show minimal lumen diameter changes for those lesions that were not post-dilated,
whereas solid lines show minimal lumen diameter change of the lesions that underwent post-dilation. Differences in acute gains were mainly
observed at the time of device implantation (Dþ1.50 mm vs. Dþ1.23 mm), whereas the gain from post-dilation was similar between the 2 arms
(Dþ0.16 mm vs. Dþ0.16 mm), when patients underwent post-dilation. IVSU ¼ intravascular ultrasound; MLA ¼ minimal lumen area; QCA ¼
quantitative coronary angiography.
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1224the Absorb arm than in the Xience arm (risk ratio:
3.04; 95% conﬁdence interval [CI]: 1.94 to 4.76)
(Table 3). Results of logistic regression analysis are
summarized in Online Table 1. Sex, age, obesity,
treated vessel, pre-procedural lumen eccentricity at
the site of MLA, presence or absence of calcium as
well as arc of calcium at the site of MLA, tissue
composition at the site of MLA were not independent
predictors for lower acute gain. The following vari-
ables were signiﬁcantly associated with lower acute
gain in the multivariate model: Absorb use, maximal
inner device or balloon diameter throughout proce-
dure, vessel and plaque areas at the MLA site, and
negative remodeling. Differences in IVUS acute gain
between Absorb and Xience were consistent across
these variables (Table 3).DISCUSSION
MAIN FINDINGS. The main ﬁndings of this study are:
lower acute gain occurred more frequently in the
Absorb arm than in the Xience arm (3.46 mm2 vs. 4.27
mm2, respectively; p < 0.001; risk ratio: 3.04; 95%
CI: 1.94 to 4.76); plaque morphology at the MLA
cross-section was not independently associated with
acute gain; and on angiography, acute device recoil
was comparable, but expansion of the device was
different. The inﬂuence of post-dilation on MLD was
somewhat limited.
IMPACT OF LESION MORPHOLOGY ON LUMEN
ENLARGEMENT. There are conﬂicting data about the
impact of lesionmorphology on lumen enlargement. In
TABLE 3 Incidence of Lower Acute Gain
Absorb Xience Risk Ratio p Value for Interaction
All patients 41% (128/313) 19% (31/167) 3.04 (1.94-4.76)
Maximal expected diameter of balloon
with or without post-dilatation
Lower tertile (#3.28) 70% (78/112) 35% (25/72) 4.31 (2.30-8.10)
Mid-tertile (>3.28, #3.40) 32% (37/117) 9% (3/34) 4.78 (1.37-16.64) 0.872
Higher tertile (>3.40) 16% (13/84) 5% (3/61) 3.54 (0.96-13.02)
Vessel area at MLA site
Lower tertile (#9.10) 67% (75/112) 45% (21/47) 2.51 (1.25-5.04)
Mid-tertile (>9.10, <12.30) 33% (35/105) 13% (7/53) 3.29 (1.35-8.02) 0.305
Higher tertile ($12.30) 19% (18/96) 5% (3/67) 4.92 (1.39-17.46)
Plaque area at MLA site
Lower tertile (#7.10) 69% (79/114) 46% (20/44) 2.71 (1.33-5.53)
Mid-tertile (>7.10, <9.95) 35% (35/101) 16% (9/58) 2.89 (1.27-6.56) 0.475
Higher tertile ($9.95) 14% (14/98) 3% (2/65) 5.25 (1.15-23.94)
Remodeling*
Negative (RI<0.88) 41% (54/132) 17% (13/75) 3.30 (1.65-6.59)
Intermediate (0.88# RI#1.00) 39% (32/83) 26% (11/43) 1.83 (0.81-4.13) 0.835
Positive (RI>1.0) 43% (40/94) 15% (7/46) 4.13 (1.67-10.18)
*Remodeling index: 7 missing data.
MLA ¼ minimal lumen area; RI ¼ remodeling index.
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1225previous reports, the expansion of drug-eluting stents
was drastically inﬂuenced by IVUS (grayscale/virtual
histology) plaque morphology (including the arc and
length of lesion calcium) or quantitative lesion site
geometry (lesion vessel area, plaque area, and plaque
burden) (16–18). In the present study, the impact of
plaque component on acute gain in lumen areawas not
retained in the multivariate analysis, although in uni-
variate analysis, higher amounts of ﬁbrotic plaque,
necrotic core, and dense calcium showed lower acute
gain in lumen area in both arms. In the present study,
presence or absence of calcium as well as the arc of
calcium by IVUS grayscale did not affect the acute gain
and device expansion at MLA (Figure 5).
DIFFERENCES IN PROCEDURAL STRATEGY BETWEEN
ABSORB AND XIENCE. Differences in acute perfor-
mance can be driven not only by differences in the
mechanical properties of the Absorb scaffold and the
Xience metallic stent but also by different initial
implantation strategies (6,19,20). Within precise
boundaries of expansion (e.g., 3.0 to 3.5 mm for a de-
vice of 3.0 mm), the stress-strain relationship of the
metallic and polymeric struts are comparable, and the
mechanical strength of the Absorb scaffold is not
different from that of the metallic stent (21). However,
when the scaffold is over-expanded (>3.5 mm for a3.0-mm device), the strut crowns begin approaching
their geometrical limit. The radial support is maxi-
mized, while their tensile strength limit is also reached
(22). Therefore, pre-dilation, optimal expansion, and
avoidance of over-expansion are encouraged during
the procedure with the Absorb device.
Maximal expected balloon diameters in cases with
or without post-dilation were similar between Absorb
and Xience. However, the ratio of post-procedural
lumen area at the site of pre-procedural MLA to the
expected inner device area calculated from the largest
balloon used during procedure was smaller in the
Absorb than in the Xience (Figure 4). This result might
imply the necessity of more aggressive strategy during
implantation and post-dilation of Absorb compared to
Xience due to the device mechanical properties (i.e.,
tensile strength and radial force).
When QCA was performed to assess MLD changes at
different phases during the procedure, differences
between the 2 armswere already signiﬁcant at the time
of device balloon expansion (Dþ1.50mm for Xience vs.
Dþ1.23 mm for Absorb; p < 0.01) (Figure 6), despite the
fact that the expected inner devices’ diameters at
implantation were similar in both arms. Acute device
recoil amounts were comparable between the 2 arms
(4). Despite less aggressive post-dilation in the Absorb
PERSPECTIVES
WHAT IS KNOWN? It is warranted that the acute
performance of Absorb matches that of metallic
stents; however, concern exists about acute expan-
sion and lumen gain with the use of Absorb.
WHAT IS NEW? Lower IVUS acute gain occurred
more frequently in the Absorb arm than in the Xience
arm. The plaque morphology at the MLA cross-section
was not independently associated with acute gain. On
angiography, device acute recoil was comparable but
expansion of the device was different.
WHAT IS NEXT? Further studies are needed to eval-
uate the impact ofmore aggressive strategies at implan-
tation, pre- and post-dilation than the technique used in
the ABSORB II trial on acute performance of Absorb.
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1226arm than in the Xience arm, the angiographic gains
from post-dilation between the 2 arms were similar
(Dþ0.16 mm vs. Dþ0.16 mm, respectively; p ¼ 0.97)
(Figure 6). These angiographic analyses implied dif-
ferences of the mechanical properties of both devices
and the necessity of different procedural strategies for
implantation.
The issue of recoil in QCA and IVUS seemingly
somewhat contradicted each other. Another possi-
bility is that the limited accuracy of the measure-
ments by QCA and IVUS due to their resolutions could
cause this contradiction. Their accuracy could be
affected differently in implanted polymeric scaffolds
and metallic stents. Moreover, the recoils were
assessed by QCA and IVUS in a different fashion and
settings. With IVUS, post-procedural MLA was
compared to the virtual expected balloon dimensions
at the time of maximal balloon inﬂation. In QCA,
recoil was assessed from the difference in diameter
between inﬂation balloon device and stented/
scaffolded diameter of the vessel post-implantation.
CLINICAL IMPLICATION. On the basis of previous
reports (23) of disrupted polymeric scaffolds due to
over-expansion, the protocol did not recommend post-
dilation of the bioresorbable scaffold device. However,
on angiography, a signiﬁcant difference in the initial
expansion was noted (Absorb < Xience). To achieve
with the Absorb an acute lumen gain equivalent to that
of the Xience, device balloon expansion with higher
pressures and/or more aggressive post-dilation should
be considered within the limits of the recommended
diameters due to the difference in inherent device
mechanical properties (i.e., tensile strength and radial
force). Because the device balloon of the Absorb is
semi-compliant, implantation with a high pressure
might result in over-expansion of the device or edge
dissection. One of the possible contributing factors
to lower acute gain in the Absorb is the lack of sys-
tematic post-dilation with a noncompliant balloon
with a diameter of 0.25 or 0.5 mm larger than the
nominal diameter of the polymeric device.
The following 3 clinical questions remain: How does
an aggressive lesion preparation (pre-dilation, rota-
tional atherectomy or cutting/scoring balloon) impact
acute gain? Can a high implantation pressure with the
Absorb device improve acute gain? How does an
aggressive post-dilation impact acute gain? These
questions should be answered in future trials.
STUDY LIMITATIONS. If the IVUS catheter could not
cross the lesion, pre-dilation with a small balloon was
performed. The incidence of pre-dilation before IVUS
was similar between the Absorb and Xience arms,
but initial lesion geometry and morphology couldnot be evaluated in 12% of lesions. The analysts in core
laboratory were not blinded to the device type, which
could result in potential bias in data acquisition. Aorto-
ostial lesions, bifurcations, chronic total occlusions,
and lesions with heavy calciﬁcation on angiography
were excluded from the present study. Thus, our
conclusions should not be extrapolated to more com-
plex lesion subsets. Lastly, in the present study, we did
not evaluate—due to the small number of the events—
the relationship between IVUS ﬁndings and clinical
events such as scaffold thrombosis that is our current
concern after implantation of Absorb.
CONCLUSIONS
At the site of pre-procedural MLA, the Absorb scaffold
showed lower acute gain than Xience stents. To
achieve acute gain equivalent to that of Xience,
Absorb deployment may require preparation of the
lesion and more aggressive strategies at implantation
and post-dilation than the technique used in the
ABSORB II trial due to the difference in inherent
device mechanical properties.
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